Haemonetics Corporation (HAE) Next Earnings Date & Expected ±5.8% Move

Per the Roarable RQD rating, HAE scores 74 out of 100, graded B and labeled "Roarable Buy — Good Risk/Reward." The five pillars are:

• Fundamental Cash Engine: 15 / 20. Per the RQD rating, this pillar reflects ROIC of 8.4% and an FCF yield of 4.78%. For an investor, this indicates the business generates a modest return on invested capital and a positive free-cash return relative to its market value, though neither figure is exceptional on its own.
• Whale 13F Flow: 17 / 20. Per the RQD rating, this pillar reflects institutional accumulation and options positioning. This is the highest pillar, suggesting institutional interest is a notable support, though the source data does not itemize the underlying 13F holdings.
• Insider Conviction: 13 / 20. Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The score is moderate; the holders section of the source data is empty, so the specific trades behind this score cannot be verified here.
• Macro Regime Fit: 13 / 20. Per the RQD rating, beta is 1 and the pillar reflects sector sensitivity. For an investor, a beta of 1 implies market-level sensitivity to broad moves, with no added amplification or dampening from the rating's view.
• Forensic Balance Sheet: 16 / 20. Per the RQD rating, this pillar reflects an Altman Z-Score of 3.89, a Piotroski F-Score of 7/9, and Debt/Equity of 1.01. This is the second-strongest pillar and suggests a balance sheet with reasonable solvency and financial-health signals, though leverage is not negligible.

Taken together, the rating points to a stock with institutional support and sound forensic readings, offset by modest cash returns and only moderate insider and macro scores. Upside drivers in the source data center on recent catalysts; valuation tradeoffs are visible in the elevated EV/EBITDA of 32.5 per the market data section, which implies a premium that depends on sustained earnings growth.

Per the profile section, Haemonetics Corporation (HAE) is a NYSE-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry, with a market capitalization of $5.5B. Per the Butterfly Supply-Chain Graph, no supply-chain links are mapped for this issuer. Not available in source data: product lines, customer base, and specific revenue mechanics beyond the sector and industry classification.

Per the SEC financials, revenue moved from $1309.1M in FY 2023 to $1334.0M in FY 2025, with operating income of $156.7M in FY 2025 versus $221.8M in FY 2024. Per the market data, gross margin is 59%, operating margin is 11.7%, and net margin is 0%. Per the RQD rating, ROIC is 8.4%, the Altman Z-Score is 3.89, the Piotroski F-Score is 7/9, and Debt/Equity is 1.01. Debt declined from $1219.8M in FY 2024 to $920.0M in FY 2025, while FCF rose to $260.4M.

Per the recent news section, six items are tagged to HAE. Four headlines reference a CSL Plasma supply deal update, one headline reports a 12-month price target raised to $120 implying 18% upside, and one headline reports Citi raising its price target to $123. The news wire flags all six items as CATALYST or MARKET WIRE, with five marked GREEN and one YELLOW. Per the same section, a TradingView item is titled "Haemonetics Corporation Estimates," which the source does not elaborate. No risk watch items are explicitly labeled in the source. No proprietary signals are listed in the Butterfly Supply-Chain Graph.

Per the Butterfly Supply-Chain Graph, supply chain is listed as NONE and butterfly links are empty, so no upstream or downstream dependencies are mapped. The news section references a CSL Plasma supply deal, which suggests a customer or partner relationship, but the source does not establish its structure or dependency weight. Sector correlations and 2nd-order bottlenecks are not available in source data.

• What are the reported EPS and P/E (TTM) figures? The source lists EPS as N/A for every period and both P/E measures as unavailable.
• What is the terms and scale of the CSL Plasma supply deal referenced in the news wire, and how much of revenue does it represent?
• Why did net income fall to $0.1M in FY 2025 and $0.2M in FY 2024 while operating income remained substantial, and what drives the gap?
• What institutional holders and insider trades underpin the Whale 13F Flow and Insider Conviction pillar scores, given the holders section is empty?
• What is the consensus analyst rating, and do the referenced price targets of $120 and $123 represent a broader consensus?